The lack of effect of SSTR2 expression or activation by a SSTR2 agonist on AIC100 activity was consistent with the observation that there was no appreciable difference in tumor killing between cohorts subjected to PET/CT imaging using SSTR2 tracer agonists (e.g., 68Ga-DOTATOC or NOTAOCT) versus those that did not receive the tracers in our previous8,10 and current studies. This evidence concerns the gene SSTR2 and neoplasm.